Background: Impaired levels or function of C1 inhibitor (C1-INH) results in angioedema
| INTRODUC TI ON

C1-INH (C1 inhibitor, C1 inactivator) is a protease inhibitor which
functions to control spontaneous activation of the classical complement pathway, as well as proteases of the fibrinolytic, clotting, and kinin pathways. 1, 2 The key role of C1-INH in regulating these pathways means that a C1-INH deficiency or impaired C1-INH function results in consumption of the early classical complement pathway proteins (C2 and C4) 3 as well as increased concentrations of the vasoactive peptide bradykinin. 4, 5 Increased bradykinin leads to vasodilation, fluid extravasation, increased capillary permeability and ultimately angioedema. 5 Angioedema can be split into two main, broad subtypesbradykinin-induced angioedema and histamine-induced angioedema. Bradykinin-induced angioedema can be caused by an abnormal concentration or function of C1-INH, as well as mutations in FXII and treatment with angiotensin-converting enzyme (ACE)
inhibitors. 6 These bradykinin-mediated forms of angioedema are distinct from histamine-induced angioedema stemming from allergic reactions, as they do not respond to conventional therapies such as antihistamines or corticosteroids. [7] [8] [9] This is crucial when deciding the appropriate treatment for patients presenting with angioedema.
Angioedema due to abnormal concentrations or function of C1-INH may be hereditary (C1-INH-HAE) or acquired (C1-INH-AAE, from here on in, abbreviated to HAE and AAE). The measurement of C1-INH concentration and function helps differentiate between angioedema due to impaired C1-INH production or function, and that
caused by other mechanisms. 10, 11 Hereditary angioedema is a rare, genetic disorder, which in the majority of patients is due to mutations in the SERPING1 gene. 
| MATERIAL S AND ME THODS
| Serum samples
Serum samples were obtained from several sources for these studies. and function results generated offsite in UKAS accredited immunology laboratories were provided to allow comparisons.
| Analytical studies
| Assay comparisons
| Sample preparation
Blood samples were collected by venepuncture, allowed to clot naturally and then the serum separated to prevent hemolysis. Samples were stored at −20°C before testing.
| Development of C1-INH-specific antiserum
Sheep anti-human C1-INH antiserum was generated by subcuta- 
| Development of C1-INH-depleted antiserum
Pooled serum was loaded on a CaptureSelect ™ C1-inhibitor Affinity 
| Measurement of C1-INH
Unless otherwise stated, C1-INH concentrations were determined using the Optilite C1 Inactivator Kit (NK019.OPT) on the Optilite turbidimetric analyzer according to the manufacturer's instructions at
The Binding Site, Birmingham (UK). 
| Assay validation
| Normal adult reference interval
The central 95 th percentile reference interval was established by measuring the C1-INH concentrations in serum samples taken from 120 healthy adult blood donors. These results were used to calculate the central 95 th percentile range.
| Assay comparison
To compare the Optilite C1-INH assay with an assay already used in a clinical laboratory, 260 samples sent for C1-INH investigation were assayed. These patients were undergoing investigation into the cause of their angioedema. The off-site laboratory results for C1-INH protein concentration were determined using a radial immunodiffusion assay (RID, The Binding Site Ltd.).
| Comparison of C1-INH protein concentration with C1-INH functional activity
C1-INH functional activity was determined using the Berichrom C1- 
| Statistical analysis
All graphs and statistical analyses were generated using GraphPad Prism version 5.04 or Analyze-it ® for Microsoft Excel programs. A P < 0.05 was considered statistically significant.
| RE SULTS
| Assay development
The C1-INH antiserum recognized C1-INH upon western blotting of pure protein, but did not detect potential interfering proteins ( Figure 1 , results shown for Factor XIa, Factor XIIa, Kallikrein, C1r, C1s, C2, C3c, C4, Factor B, and Properdin). Assay imprecision was calculated within run and between runs, days, batches, and instruments using five samples with different C1-INH concentrations (Table 1) . Percentage CVs within run, between runs, between days and between batches were all between 0.5% and 5.7%. The total assay imprecision was between 4.7% and 7.6%
| Assay validation
for all samples. The addition of chyle, hemoglobin, bilirubin, or triglyceride caused minimal interference with the measurement of C1-INH at the concentrations tested (Table 2 ). 
| Normal adult reference interval
| Assay comparison
The concentrations obtained using the Optilite C1-INH assay were 
| Comparison of C1-INH protein concentration with C1-INH functional activity
There was also a significant correlation between the C1-INH concentration obtained from the Optilite assay and the C1-INH functional measurements (P < 0.0001, R 2 = 0.84) (Figure 4 ). 
| D ISCUSS I ON
In this study, we have described the development and validation of Here, we provide a comparison between the high-throughput, automated assay, and an existing method used routinely in the clinical laboratory. To ensure the results obtained in the Optilite assay were comparable to those generated using the predicate assay, a comparison was performed using 260 samples sent for C1-INH investigation. These patients were undergoing investigation into the cause of their angioedema. The Optilite assay results correlated strongly with those generated with the predicate method.
All patients tested with Type I HAE and AAE in this study were identified as having C1-INH concentrations below this normal range.
Timely diagnosis of these patients is crucial, as these disorders can be fatal. Studies suggest mortality in HAE to be approximately 30% before improvements in the diagnosis and treatment of the diseaseprimarily due to asphyxiation caused by laryngeal edema. 21, 27, 28 Improvements in HAE therapies mean that acute attacks can be effectively treated either in hospital or at home and in those with a high attack frequency prophylactic therapy has been shown to be effective in reducing attacks. Accurate and early diagnosis is therefore key to ensuring these patients receive timely and appropriate care. C1-INH testing and achieving a definitive diagnosis is also important for the reimbursement of specific therapies in some countries, emphasizing the requirement for laboratory tests that aid in specific diagnoses.
The three Type II HAE patients tested here had normal protein concentrations of C1-INH by both the predicate assay and the Optilite assay. It is known that these patients have normal protein concentrations but reduced function, and functional C1-INH testing is therefore required to identify these patients.
As expected, the results provided from the clinical laboratory demonstrate these patients do indeed have greatly reduced C1-INH function.
As a consequence of uncontrolled complement activation, serum C4 is also low in the majority of patients with HAE 15, 23 and AAE, 29 and due to the ease, cost and availability of this assay, it is often used to Results were analyzed using linear regression analysis "request manage" access to C1-INH assays in the UK. 26 However, several studies have now shown that normal serum C4 does not always exclude the diagnosis of HAE. 26, 30 One recent study demonstrated low serum C4 had only 71% sensitivity for HAE diagnosis, whereas low C1-INH had 97% sensitivity for Type I HAE 26 -demonstrating the importance of measuring C1-INH protein concentration to aid the diagnosis of these patients.
| CON CLUS ION
In conclusion, the Optilite C1-INH assay provides a simple, rapid and precise method for the measurement of C1-INH in patient serum samples, and could be used to aid in the diagnosis of angioedema caused by C1-INH deficiencies.
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